Contact

Our portfolio

PacingCure

PacingCure is pioneering gene therapy solutions to cure heart conditions that results in pacing issues. The company focuses on developing biological pacemakers for patients who cannot use conventional electronic pacemaker devices. Their research explores various transgenes and delivery systems to modulate heart pacing. PacingCure is dedicated to advancing cardiac care through innovative gene therapy.

  • Institute: Amsterdam UMC
Industry: Cardiology, Gene Therapy, Therapeutics
  • Founding year: 2016
Visit website

Want to get in contact about PacingCure?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Quantum Gateway Solutions
Providing quantum-safe security solutions to protect organizations from future cyber threats.

OpticsFoundry

OpticsFoundry
Revolutionizing optical circuit manufacturing by offering robotically assembled and modular optical circuit boards that are easy to design, order, and deploy.
Rsouth Antibodies
Developing therapeutic antibodies, including the blockbuster RSV drug Nirsevimab.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Quantum Gateway Solutions
Providing quantum-safe security solutions to protect organizations from future cyber threats.

OpticsFoundry

OpticsFoundry
Revolutionizing optical circuit manufacturing by offering robotically assembled and modular optical circuit boards that are easy to design, order, and deploy.
Rsouth Antibodies
Developing therapeutic antibodies, including the blockbuster RSV drug Nirsevimab.
Explore full AAV portfolio
Contact